First People's Hospital

68Ga-DOTA/NOTA-FAPI-04 is a radiopharmaceutical small-molecule imaging agent in Phase 1 clinical development sponsored by The First People's Hospital of Lianyungang for tumor imaging and characterization. The program, internally coded FirstAHFujian3, leverages gallium-68 (68Ga) labeling chemistry combined with fibroblast activation protein inhibitor (FAPI) scaffolds to enable positron emission tomography (PET) imaging of tumors. The mechanism of action, specific molecular target, and route of administration have not yet been disclosed. As of September 2020, the program remains active in Phase 1 evaluation. The compound is being evaluated under clinical trial NCT04499365 in China, with regulatory status indicating ongoing clinical trials under the China NMPA framework. No partnership arrangements, licensing agreements, or peak sales projections have been disclosed. The program represents early-stage development of a potentially differentiated imaging modality in the competitive oncology diagnostic space.

Tumor imaging represents a critical unmet need in oncology, where accurate, early detection and characterization directly impact patient outcomes, treatment selection, and monitoring. Fibroblast activation protein (FAP) has emerged as a promising imaging biomarker in cancer, as FAP-expressing cancer-associated fibroblasts are prevalent in the tumor microenvironment across multiple solid malignancies. 68Ga-labeled FAPI agents offer potential advantages over conventional imaging modalities through improved spatial resolution, quantification capability, and reduced radiation burden compared to fluorodeoxyglucose (FDG)-PET in certain tumor types.

The competitive landscape includes established radiopharmaceuticals such as Dotarem (gadolinium-based contrast, Guerbet) and emerging FAPI-based imaging agents. The market relevance is substantial given the global prevalence of cancer and the clinical need for improved diagnostic accuracy. Patient populations span multiple solid tumor types where FAP expression is elevated. The commercial significance is considerable, as successful development could establish a new standard-of-care imaging modality in oncology diagnostics, with applications across staging, treatment planning, and response assessment.

68Ga-DOTA/NOTA-FAPI-04 is a small-molecule radiopharmaceutical combining gallium-68 (68Ga) radiolabeling with fibroblast activation protein inhibitor (FAPI) chemistry. The compound utilizes chelation chemistry (DOTA or NOTA chelators) to stably bind 68Ga for PET imaging applications. The specific molecular target, route of administration, and detailed mechanism of action have not yet been disclosed in available documentation. Related therapies in development include other FAPI-based imaging agents and conventional tumor imaging modalities. First approval status and patent information are not yet disclosed.

• China (NMPA): 68Ga-DOTA/NOTA-FAPI-04 is in clinical trials status under NMPA oversight, as evidenced by clinical trial registration NCT04831034.
• United States (FDA): Regulatory status not yet disclosed.
• Europe (EMA): Regulatory status not yet disclosed.
• Japan (PMDA): Regulatory status not yet disclosed.

• Strategic Positioning: The program represents early-stage development of a FAP-targeting radiopharmaceutical, a mechanism gaining traction in oncology imaging. The sponsor's institutional affiliation (The First People's Hospital of Lianyungang) suggests development within the Chinese healthcare system, with potential for regional market penetration.
• Competitive Implications: Success would establish a differentiated imaging modality complementary to or potentially superior to conventional FDG-PET and contrast-enhanced MRI in specific tumor types. The competitive field includes both established imaging standards and emerging FAPI-based agents, creating a crowded but growing market segment.
• Development Catalysts: Progression from Phase 1 to Phase 2 would represent the next critical milestone, requiring demonstration of safety, tolerability, and preliminary imaging efficacy. Publication of Phase 1 data would provide visibility into biodistribution, dosimetry, and preliminary clinical performance.
• Expected Milestones: Phase 1 completion and Phase 2 initiation timelines are not yet disclosed. Regulatory approval pathway and commercial development strategy remain undisclosed.